| 1 |
Review Biomarkers for Parkinson's disease. 2009
Graeber MB. · The Athenaeum, Pall Mall, London SW1Y 5ER, UK. · Exp Neurol. · Pubmed #19166835 No free full text.
Abstract: With the advent of systems biological concepts there has been a surge of interest in biological factors, or biomarkers that can be measured and which allow the identification of individuals at risk. Biomarkers for Parkinson's disease have been identified which provide evidence of systemic metabolic dysregulation in this disorder. Such biomarkers can be studied in blood, serum and plasma but also in CSF and urine, and the study by Hoepken et al. in this issue has even made use of skin fibroblasts. The authors report on the induction of alpha-synuclein expression and suggest that the expression changes described might potentially allow objective PD patient diagnosis in an accessible, peripheral tissue. This mini-review aims to provide a broader perspective on PD functional genomics and seeks to illustrate in a systems biological context why the findings by Hoepken and colleagues are of clinical significance.
|
| 2 |
Review Nuclear hormone and orphan receptors: their role in neuronal differentiation and cytoprotection and in the pathogenesis of Parkinson's disease. 2003
Malaspina A, Pearce RK, Graeber MB. · Department of Neuropathology, Division of Neuroscience and Psychological Medicine, Faculty of Medicine, Imperial College London, Charing Cross Campus, London, UK. · Dev Neurosci. · Pubmed #14966378 No free full text.
Abstract: Human nuclear hormone receptors (NHR) and orphan receptors (NOR) act as transcription factors in response to a wide range of circulating hormones and unknown ligands. A role for NHR and NOR in disorders of the subcortical dopaminergic pathways such as Parkinson's disease (PD) is suggested by a wealth of recent data including experimental observations. Both classes of receptors promote the formation of specific neuronal identities, tissue patterning during embryonic development and the maturation of vulnerable monoaminergic and cholinergic neurons. NHR and NOR are also known to exert a neuroprotective function on adult neurons. The scope of this review is to revisit the functional profile of these receptors with particular reference to their activity in the development of selected neuronal populations relevant to the pathophysiology of PD and to discuss how they may relate to the neuropathological and clinical expression of the disease.
|
| 3 |
Review Mechanisms of cell death in neurodegenerative diseases: fashion, fiction, and facts. 2002
Graeber MB, Moran LB. · Department of Neuropathology, Faculty of Medicine, Imperial College, London, United Kingdom. · Brain Pathol. · Pubmed #12146806 No free full text.
Abstract: Apoptosis has become a most popular concept of cell death. However, the term is now so widely used and employed in such general terms in relation to neurological diseases that its application is very problematic. In addition, with the exception of developmental conditions, there is essentially no evidence of apoptosis fulfilling the criteria of its classical definition in any of the important human neurodegenerative diseases, including Alzheimer's, Parkinson's, Huntington's, Amyotrophic Lateral Sclerosis, and Creutzfeldt-Jakob disease. Importantly, a number of new cell death forms have been described in the literature and there is good reason to pay attention to these emerging concepts as they may provide a rationale for the development of disease-specific therapies.
|
| 4 |
Review Role of mitochondria in Parkinson disease. 1999
Kösel S, Hofhaus G, Maassen A, Vieregge P, Graeber MB. · Labor für Molekulare Neuropathologie, Institut für Neuropathologie, Ludwig-Maximilians-Universität, München, Germany. · Biol Chem. · Pubmed #10494835 No free full text.
Abstract: The cause of the selective degeneration of nigrostriatal neurons in Parkinson disease (PD) has remained largely unknown. Exceptions include rare missense mutations in the alpha-synuclein gene on chromosome 4, a potentially pathogenic mutation affecting the ubiquitin pathway, and mutations in the parkin gene on chromosome 6. However, unlike classical PD, the latter syndrome is not associated with the formation of typical Lewy bodies. In contrast, a biochemical defect of complex I of the mitochondrial respiratory chain has been described in a relatively large group of confirmed PD cases. Recent cybrid studies indicate that the complex I defect in PD has a genetic cause and that it may arise from mutations in the mitochondrial DNA. Sequence analysis of the mitochondrial genome supports the view that mitochondrial point mutations are involved in PD pathogenesis. However, although mitochondria function as regulators in several known forms of cell death, their exact involvement in PD has remained unresolved. This is of relevance because classical apoptosis does not appear to play a major role in the degeneration of the parkinsonian nigra.
|
| 5 |
Article Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease. 2009
Kalaitzakis ME, Christian LM, Moran LB, Graeber MB, Pearce RK, Gentleman SM. · Department of Clinical Neuroscience, Neuropathology Unit, Division of Neuroscience and Mental Health, Imperial College Healthcare NHS Trust, London, UK. · Parkinsonism Relat Disord. · Pubmed #18602855 No free full text.
Abstract: The pathological basis of dementia and visual hallucinations in Parkinson's disease (PD) is not yet fully understood. To investigate this further we have conducted a clinico-pathological study based on 30 post-mortem PD brains. PD cases were stratified into groups according to clinical characteristics as follows: (1) cognitively intact (n=9); (2) cases with severe dementia and visual hallucinations (n=12); (3) cases with severe dementia and no visual hallucinations (n=4); and (4) cases with severe visual hallucinations and no dementia (n=5). The extent of alpha-synuclein (alphaSyn), tau and amyloid beta peptide (Abeta) deposition was then examined in the CA2 sector of the hippocampus and in neocortical and subcortical areas known to subserve cognitive function. We find that dementia in PD is significantly associated with alphaSyn in the anterior cingulate gyrus, superior frontal gyrus, temporal cortex, entorhinal cortex, amygdaloid complex and CA2 sector of the hippocampus. Abeta in the anterior cingulate gyrus, entorhinal cortex, amygdaloid complex and nucleus basalis of Meynert is also associated with dementia as is tau in the CA2 sector of the hippocampus. alphaSyn burden in the amygdala is strongly related to the presence of visual hallucinations but only in those PD cases with concomitant dementia. Statistical analysis revealed that alphaSyn burden in the anterior cingulate gyrus could differentiate demented from non-demented PD cases with high sensitivity and specificity. We conclude that alphaSyn in limbic regions is related to dementia in PD as well as to visual hallucinations when there is an underlying dementia.
|
| 6 |
Article Striatal beta-amyloid deposition in Parkinson disease with dementia. 2008
Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. · University Department of Neuropathology, Division of Neuroscience and Mental Health, Imperial College London, Hammersmith Hospitals Trust, London, UK. · J Neuropathol Exp Neurol. · Pubmed #18219254 No free full text.
Abstract: Dementia is common in Parkinson disease (PD), although its anatomic and pathologic substrates remain undefined. Recently, striatal abnormalities in Lewy body diseases have been described, but their clinical relevance is not clear. Thirty PD cases from the United Kingdom Parkinson's Disease Society Tissue Bank were grouped as demented (PDD; n = 16) and nondemented (PD; n = 14) based on a review of clinical records. The extent of alpha-synuclein, tau, and amyloid beta peptide (Abeta) deposition in the caudate nucleus, putamen, and nucleus accumbens was assessed. All cases showed severe dopaminergic striatal terminal denervation based on tyrosine hydroxylase immunohistochemistry. Alpha-synuclein and tau deposition in the striatum were rare in both groups, but the Abeta burden was significantly greater in the striatum of PD cases with dementia than present in the nondemented PD group. Striatal Abeta deposition was type-independent of Alzheimer disease changes in the cortex and was minimal in nondemented PD cases. We conclude that Abeta deposition in the striatum strongly correlates with dementia in PD.
|
| 7 |
Article Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation. free! 2008
Moran LB, Graeber MB. · University Department of Neuropathology, Imperial College, University of London, Hammersmith Hospitals Trust, London, UK. · Neurogenetics. · Pubmed #18196299 links to free full text
Abstract: We have previously established a first whole genome transcriptomic profile of sporadic Parkinson's disease (PD). After extensive brain tissue-based validation combined with cycles of iterative data analysis and by focusing on the most comparable cases of the cohort, we have refined our analysis and established a list of 892 highly dysregulated priority genes that are considered to form the core of the diseased Parkinsonian metabolic network. The substantia nigra pathways, now under scrutiny, contain more than 100 genes whose association with PD is known from the literature. Of those, more than 40 genes belong to the highly significantly dysregulated group identified in our dataset. Apart from the complete list of 892 priority genes, we present pathways revealing PD 'hub' as well as 'peripheral' network genes. The latter include Lewy body components or interact with known PD genes. Biological associations of PD with cancer, diabetes and inflammation are discussed and interactions of the priority genes with several drugs are provided. Our study illustrates the value of rigorous clinico-pathological correlation when analysing high-throughput data to make optimal use of the histopathological phenome, or morphonome which currently serves as the key diagnostic reference for most human diseases. The need for systematic human tissue banking, following the highest possible professional and ethical standard to enable sustainability, becomes evident.
|
| 8 |
Article The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging. 2008
Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. · University Department of Neuropathology, Division of Neuroscience and Mental Health, Imperial College London, Hammersmith Hospitals Trust, London, UK. · Neuropathol Appl Neurobiol. · Pubmed #18053026 No free full text.
Abstract: AIMS: It has been proposed that alpha-synuclein (alpha Syn) pathology in Parkinson's disease (PD) spreads in a predictable caudo-rostral way with the earliest changes seen in the dorsal motor nucleus of the vagus nerve (DMV). However, the reliability of this stereotypical spread of alpha Syn pathology has been questioned. In addition, the comparative occurrence of alpha Syn pathology in the spinal cord and brain has not been closely studied. METHODS: In order to address these issues, we have examined 71 cases of PD from the UK Parkinson's Disease Society Tissue Bank at Imperial College, London. The incidence and topographic distribution of alpha Syn pathology in several brain regions and the spinal cord were assessed. RESULTS: The most affected regions were the substantia nigra (SN; in 100% of cases) followed by the Nucleus Basalis of Meynert (NBM) in 98.5%. Fifty-three per cent of cases showed a distribution pattern of alpha Syn compatible with a caudo-rostral spread of alpha Syn through the PD brain. However, 47% of the cases did not fit the predicted spread of alpha Syn pathology and in 7% the DMV was not affected even though alpha Syn inclusions were found in SN and cortical regions. We also observed a high incidence of alpha Syn in the spinal cord with concomitant affection of the DMV and in a few cases in the absence of DMV involvement. CONCLUSIONS: Our results demonstrate a predominant involvement of the SN and NBM in PD but do not support the existence of a medullary induction site of alpha Syn pathology in all PD brains.
|
| 9 |
Article Neuronal pentraxin II is highly upregulated in Parkinson's disease and a novel component of Lewy bodies. free! 2008
Moran LB, Hickey L, Michael GJ, Derkacs M, Christian LM, Kalaitzakis ME, Pearce RK, Graeber MB. · Imperial College London and Hammersmith Hospitals Trust, University Department of Neuropathology, Charing Cross campus, Fulham Palace Road, London W6 8RF, UK. · Acta Neuropathol. · Pubmed #17987278 links to free full text
Abstract: Neuronal pentraxin II (NPTX2) is the most highly upregulated gene in the Parkinsonian substantia nigra based on our whole genome expression profiling results. We show here that it is a novel component of Lewy bodies and Lewy neurites in sporadic Parkinson's disease (PD). NPTX2 is also known as the neuronal activity-regulated protein (Narp), which is secreted and involved in long-term neuronal plasticity. Narp further regulates AMPA receptors which have been found to mediate highly selective non-apoptotic cell death of dopaminergic neurons. NPTX2/Narp is found in close association with alpha-synuclein aggregates in both substantia nigra and cerebral cortex in PD but unlike alpha-synuclein gene expression, which is down-regulated in the Parkinsonian nigra, NPTX2 could represent a driver of the disease process. In view of its profound (>800%) upregulation and its established role in synaptic plasticity as well as dopaminergic nerve cell death, NPTX2 is a very interesting novel player which is likely to be involved in the pathway dysregulation which underlies PD.
|
| 10 |
Article The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability. 2007
Duke DC, Moran LB, Pearce RK, Graeber MB. · University Department of Neuropathology, Faculty of Medicine, Division of Neuroscience and Mental Health, Imperial College London and Hammersmith Hospitals Trust, Charing Cross campus, Fulham Palace Road, London, W6 8RF, UK. · Neurogenetics. · Pubmed #17211632 No free full text.
Abstract: Sporadic Parkinson's disease (PD) is characterized by progressive death of dopaminergic neurons within the substantia nigra. However, pathological cell death within this nucleus is not uniform. In PD, the lateral tier of the substantia nigra (SNl) degenerates earlier and more severely than the more medial nigral component (SNm). The cause of this brain regional vulnerability remains unknown. We have used DNA oligonucleotide microarrays to compare gene expression profiles from the SNl to those of the SNm in both PD and control cases. Genes expressed more highly in the PD SNl included the cell death gene, p53 effector related to PMP22, the tumour necrosis factor (TNF) receptor gene, TNF receptor superfamily, member 21, and the mitochondrial complex I gene, NADH dehydrogenase (ubiquinone) 1beta subcomplex, 3, 12 kDa (NDUFbeta3). Genes that were more highly expressed in PD SNm included the dopamine cell signalling gene, cyclic adenosine monophosphate-regulated phosphoprotein, 21 kDa, the activated macrophage gene, stabilin 1, and two glutathione peroxidase (GPX) genes, GPX1 and GPX3. Thus, there is increased expression of genes encoding pro-inflammatory cytokines and subunits of the mitochondrial electron transport chain, and there is a decreased expression of several glutathione-related genes in the SNl suggesting a molecular basis for pathoclisis. Importantly, some of the genes that are differentially regulated in the SNl are known to be expressed highly or predominantely in glial cells. These findings support the view that glial cells can be primarily affected in PD emphasizing the importance of using a whole tissue approach when investigating degenerative CNS disease.
|
| 11 |
Article Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. 2006
Duke DC, Moran LB, Kalaitzakis ME, Deprez M, Dexter DT, Pearce RK, Graeber MB. · Department of Neuropathology, Imperial College London and Hammersmith, Hospitals Trust, Charing Cross Campus, Fulham Palace Road, London, W6 8RF, UK. · Neurogenetics. · Pubmed #16699787 No free full text.
Abstract: There is growing evidence that dysfunction of the mitochondrial respiratory chain and failure of the cellular protein degradation machinery, specifically the ubiquitin-proteasome system, play an important role in the pathogenesis of Parkinson's disease. We now show that the corresponding pathways of these two systems are linked at the transcriptomic level in Parkinsonian substantia nigra. We examined gene expression in medial and lateral substantia nigra (SN) as well as in frontal cortex using whole genome DNA oligonucleotide microarrays. In this study, we use a hypothesis-driven approach in analysing microarray data to describe the expression of mitochondrial and ubiquitin-proteasomal system (UPS) genes in Parkinson's disease (PD). Although a number of genes showed up-regulation, we found an overall decrease in expression affecting the majority of mitochondrial and UPS sequences. The down-regulated genes include genes that encode subunits of complex I and the Parkinson's-disease-linked UCHL1. The observed changes in expression were very similar for both medial and lateral SN and also affected the PD cerebral cortex. As revealed by "gene shaving" clustering analysis, there was a very significant correlation between the transcriptomic profiles of both systems including in control brains. Therefore, the mitochondria and the proteasome form a higher-order gene regulatory network that is severely perturbed in Parkinson's disease. Our quantitative results also suggest that Parkinson's disease is a disease of more than one cell class, i.e. that it goes beyond the catecholaminergic neuron and involves glia as well.
|
| 12 |
Article Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. 2006
Moran LB, Duke DC, Deprez M, Dexter DT, Pearce RK, Graeber MB. · University Department of Neuropathology, Division of Neuroscience and Mental Health, Imperial College London and Hammersmith Hospitals Trust, Charing Cross campus, Fulham Palace Road, London, W6 8RF, UK. · Neurogenetics. · Pubmed #16344956 No free full text.
Abstract: We have used brain tissue from clinically well-documented and neuropathologically confirmed cases of sporadic Parkinson's disease to establish the transcriptomic expression profile of the medial and lateral substantia nigra. In addition, the superior frontal cortex was analyzed in a subset of the same cases. DNA oligonucleotide microarrays were employed, which provide whole human genome coverage. A total of 570 genes were found to be differentially regulated at a high level of significance. A large number of differentially regulated expressed sequence tags were also identified. Levels of mRNA sequences encoded by genes of key interest were validated by means of quantitative real-time polymerase chain reaction (PCR). Comparing three different normalization procedures, results based on the recently published GeneChip Robust Multi Array algorithm were found to be the most accurate predictor of real-time PCR results. Several new candidate genes which map to PARK loci are reported. In addition, the DNAJ family of chaperones is discussed in the context of Parkinson's disease pathogenesis.
|
| 13 |
Article Electron microscopy of tissue adherent to explanted electrodes in dystonia and Parkinson's disease. free! 2004
Moss J, Ryder T, Aziz TZ, Graeber MB, Bain PG. · Electron Microscopy Unit, Department of Histopathology, Charing Cross Hospital, Hammersmith Hospitals NHS Trust, London, UK. · Brain. · Pubmed #15329356 links to free full text
Abstract: Deep brain stimulation (DBS) is used to treat a variety of severe medically intractable movement disorders, including Parkinson's disease, tremor and dystonia. There have been few studies examining the effect of chronic DBS on the brains of Parkinson's disease patients. Most of these post mortem studies concluded that chronic DBS caused mild gliosis around the lead track and did not damage brain tissue. There have been no similar histopathological studies on brains from dystonic patients who have undergone DBS. In this study, our objective was to discover whether tissue would be attached to DBS electrodes removed from patients for routine clinical reasons. We hoped that by examining explanted DBS electrodes using scanning (SEM) and/or transmission (TEM) electron microscopy we might visualize any attached tissue and thus understand the electrode-human brain tissue interaction more accurately. Initially, SEM was performed on one control DBS electrode that had not been implanted. Then 21 (one subthalamic nucleus and 20 globus pallidus internus) explanted DBS electrodes were prepared, after fixation in 3% glutaraldehyde, for SEM (n = 9) or TEM (n = 10), or both (n = 2), according to departmental protocol. The electrodes were sourced from two patients with Parkinson's disease, one with myoclonic dystonia, two with cervical dystonia and five with primary generalized dystonia, and had been in situ for 11 and 31 months (Parkinson's disease), 16 months (myoclonic dystonia), 14 and 24 months (cervical dystonia) and 3-24 months (primary generalized dystonia). Our results showed that a foreign body multinucleate giant cell-type reaction was present in all TEM samples and in SEM samples, prewashed to remove surface blood and fibrin, regardless of the diagnosis. Some of the giant cells were >100 microm in diameter and might have originated from either fusion of parenchymal microglia, resident perivascular macrophage precursors and/or monocytes/macrophages invading from the blood stream. The presence of mononuclear macrophages containing lysosomes and sometimes having conspicuous filopodia was detected by TEM. Both types of cell contained highly electron-dense inclusions, which probably represent phagocytosed material. Similar material, the exact nature of which is unknown, was also seen in the vicinity of these cells. This reaction was present irrespective of the duration of implantation and may be a response to the polyurethane component of the electrodes' surface coat. These findings may be relevant to our understanding of the time course of the clinical response to DBS in Parkinson's disease and various forms of dystonia, as well as contributing to the design characteristics of future DBS electrodes.
|
| 14 |
Article Inter-laboratory comparison of DNA preservation in archival paraffin-embedded human brain tissue from participating centres on four continents. 2001
Kösel S, Grasbon-Frodl EM, Arima K, Chimelli L, Hahn M, Hashizume Y, Hulette C, Ikeda K, Jacobsen PF, Jones M, Kobayashi M, Love S, Mizutani T, Rosemberg S, Sasaki A, Smith TW, Takahashi H, Vortmeyer AO, Graeber MB. · Department of Neuropathology, Imperial College School of Medicine, London, UK. · Neurogenetics. · Pubmed #11523568 No free full text.
Abstract: DNA extracted from formalin-fixed and paraffin-embedded brain tissue is known to contain as yet ill-characterized inhibitors of the PCR process. As part of a project that aims to clarify the role of mitochondrial DNA sequence variation in human neurodegenerative diseases using DNA from various ethnic backgrounds, we have investigated factors that influence the preservation of archival DNA and its suitability for PCR. In this study, neuropathological tissue samples were analysed that had been routinely processed in 18 international centres on four continents. Following DNA extraction, PCR amplification of mitochondrial and nuclear DNA sequences was performed with and without additional purification of the template DNA. In addition, the DNA used for PCR was analysed by HPLC. Phosphate-buffered formalin proved to be a superior fixative compared with unbuffered aldehyde: DNA extraction resulted in greater yields, the molecular weight of the isolated DNA was higher and PCR was more successful. PCR inhibitors were identified as (1) high concentrations of small (<300 bp) DNA fragments that competitively compete with template DNA and (2) contaminants of the DNA template solution including denatured protein that cannot be completely removed by phenolic extraction. HPLC analysis did not reveal significant qualitative differences between DNA isolated from fresh-frozen tissue samples and DNA recovered from formalin-fixed, paraffin-embedded brain tissue. The fact that DNA could be amplified from the majority of tissue specimens in this study suggests that rare diseases and diseases where ethnic background plays an important role can be sampled for genetic polymorphism analysis on a global scale using archival neuropathological collections.
|
| 15 |
Article Parkinson disease: analysis of mitochondrial DNA in monozygotic twins. 2000
Kösel S, Grasbon-Frodl EM, Hagenah JM, Graeber MB, Vieregge P. · Labor für Molekulare Neuropathologie, Institut für Neuropathologie, Ludwig-Maximilians-Universität, Munich, Germany. · Neurogenetics. · Pubmed #10983718 No free full text.
Abstract: We have sequenced all mitochondrial complex I and tRNA genes in five pairs of monozygotic twins with a longitudinal diagnosis of idiopathic Parkinson disease (PD). At the time of molecular genetic analysis, four of the pairs were discordant for PD. Five novel homoplasmic sequence variants, including two missense mutations (ND2 4924 G/A, ND3 10192 C/T), were detected in mitochondrial genes of complex I in four of the pairs. In addition, a total of 20 known polymorphisms affecting both complex I and tRNA genes was found. Importantly, mitochondrial DNA sequences were identical in diseased and non-affected siblings of each pair. Our results demonstrate that missense mutations of mitochondrial complex I may occur in clinically discordant parkinsonian twins, questioning the direct pathogenic relevance of at least some of these mutations.
|
| 16 |
Article The alpha1-antichymotrypsin A-allele in German Parkinson disease patients. 1999
Grasbon-Frodl EM, Egensperger R, Kösel S, Krüger R, Riess O, Mehraein P, Graeber MB. · Molecular Neuropathology Laboratory, Institute of Neuropathology, Ludwig-Maximilians-University, Munich, Federal Republic of Germany. · J Neural Transm. · Pubmed #10907731 No free full text.
Abstract: An increased frequency of the A-allele of the alpha-antichymotrypsin (ACT) gene has been recently described in Japanese patients suffering from Parkinson disease (PD). In the present study, we have analyzed 62 German PD patients with regard to their ACT and APOE genotypes and compared them to 53 controls without clinical or pathological evidence of neurodegenerative disease. The A-allele frequency was 47% in PD patients compared to 54% in control cases excluding ACT as a major susceptibility factor for PD in the Caucasian population. Yet, ACT-A allele frequencies were significantly different (p < 0.001) between Japanese and German controls. Therefore, although our data do not suggest that the alpha1-ACT polymorphism is a significant risk factor for the development of PD, a consideration of differences in genetic background seems warranted when evaluating susceptibility factors for neurodegenerative disease.
|
| 17 |
Article Two novel point mutations of mitochondrial tRNA genes in histologically confirmed Parkinson disease. 1999
Grasbon-Frodl EM, Kösel S, Sprinzl M, von Eitzen U, Mehraein P, Graeber MB. · Molecular Neuropathology Laboratory, Institute of Neuropathology, Ludwig-Maximilians-University, D-80337 Munich, Germany. · Neurogenetics. · Pubmed #10369889 No free full text.
Abstract: Mutations in mitochondrially encoded tRNA genes have been described in a variety of neurological disorders. One such mutation, the A to G transition at nucleotide position 4336 of the mitochondrial tRNA(Gln) gene, has been associated with both Alzheimer and Parkinson disease. We have now performed a complete sequence analysis of all 22 mitochondrially encoded tRNA genes in 20 cases of histologically proven idiopathic Parkinson disease. Genomic DNA extracted from the substantia nigra of frozen or formalin-fixed and paraffin-embedded brains was used for amplification by polymerase chain reaction followed by automated sequencing. Two new homoplasmic point mutations were detected in the genes for tRNA(Thr) (15950 G/A) and tRNA(Pro) (15965 T/C) in 1 patient each. Restriction enzyme digestion revealed absence of the 15950 G/A mutation in 96 controls and in 40 cases of neuropathologically confirmed Alzheimer disease. The 15965 T/C mutation was shown to be absent from 100 control subjects and 47 Alzheimer cases. In addition to the two novel mutations, six known sequence variants were detected in a total of 6 different patients in the genes for tRNA(Asp) (G7521A, 1), tRNA(Arg) (T10463C, 1), tRNA(LeuCUN) (A12308G, 2), and tRNA(Thr) (A15924G, 1; G15928A, 2), including 1 patient carrying the tRNA(Gln) (A4336G) mutation. The G15950A transition affects position 70 of the aminoacyl acceptor stem of tRNA(Thr), which has been implicated as a recognition element for threonyl-tRNA synthetase and, at least in some tRNAs, in the processing of primary mitochondrial transcripts. The T15965C point mutation in the mitochondrial tRNA(Pro) gene alters position 64 of the TpsiC stem. The corresponding nucleotide in bacterial aminoacyl-tRNAs is involved in the interaction with elongation factor Tu. Thus, the two novel mutations are likely to be of functional relevance and could contribute to dopaminergic nerve cell death in affected individuals.
|
| 18 |
Article Analysis of mitochondrial targeting sequence and coding region polymorphisms of the manganese superoxide dismutase gene in German Parkinson disease patients. 1999
Grasbon-Frodl EM, Kösel S, Riess O, Müller U, Mehraein P, Graeber MB. · Molecular Neuropathology Laboratory, Institute of Neuropathology, Ludwig-Maximilians-University, Munich, D-80337, Germany. · Biochem Biophys Res Commun. · Pubmed #10049782 No free full text.
Abstract: Two polymorphisms of the MnSOD gene, Ile58Thr and Ala9Val, have been associated with Parkinson disease (PD). The Ile58Thr amino acid exchange affects the stability at the tetrameric interface of the enzyme and reduces the enzymatic activity of MnSOD while the Ala/Val substitution at position -9 of the mitochondrial targeting sequence (MTS) may lead to misdirected intracellular trafficking. We have analyzed 63 German Caucasian PD patients for possible sequence variation in the MTS as well as in exon 3 of the MnSOD gene. All 63 PD patients analyzed exhibited a T at nucleotide position 5777 in exon 3 of the MnSOD gene corresponding to ATA, or Ile at the peptide level, and no other sequence variants were found. In addition, both alleles of the Ala9Val polymorphism in the MTS of MnSOD were equally distributed between German PD patients and controls excluding this gene variant as a risk factor for PD in Caucasian subjects.
|
| 19 |
Minor Parkinson disease: extranigral, multisystem, and {alpha}-synuclein "plus". 2009
Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. · No affiliation provided · Arch Neurol. · Pubmed #19597100 No free full text.
This publication has no abstract.
|
| 20 |
Minor Evidence against a reliable staging system of alpha-synuclein pathology in Parkinson's disease. 2009
Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. · No affiliation provided · Neuropathol Appl Neurobiol. · Pubmed #19187066 No free full text.
This publication has no abstract.
|
| 21 |
Minor Controversies over the staging of alpha-synuclein pathology in Parkinson's disease. 2008
Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. · No affiliation provided · Acta Neuropathol. · Pubmed #18446352 No free full text.
This publication has no abstract.
|
| 22 |
Minor Parkinson's disease: an update. 2003
Graeber MB, Dexter D, Pearce RK, Reynolds R. · Department of Neuropathology, Division of Neuroscience and Psychological Medicine, Imperial College London, Faculty of Medicine, Charing Cross Campus, Fulham Palace Road, London W6 8RF, UK. · Neuropathol Appl Neurobiol. · Pubmed #14507344 No free full text.
This publication has no abstract.
|
| 23 |
Minor Sequence analysis of the MTCYB gene in Parkinson disease. 2000
von Eitzen U, Kösel S, Grasbon-Frodl EM, Egensperger R, Graeber MB. · No affiliation provided · Neurogenetics. · Pubmed #11085598 No free full text.
This publication has no abstract.
|
|
|